Literature DB >> 25631523

The Effect of Chronic Anabolic-Androgenic Steroid Use on Tp-E Interval, Tp-E/Qt Ratio, and Tp-E/Qtc Ratio in Male Bodybuilders.

Elnur Alizade1, Anıl Avcı1, Serdar Fidan1, Mustafa Tabakçı1, Mustafa Bulut1, Regayip Zehir2, Zeki Simsek1, Mert Evlice1, Uğur Arslantaş1, Hakan Çakır1, Mehmet Yunus Emiroglu1, Mustafa Akçakoyun1.   

Abstract

BACKGROUND: The chronic consumption of androgenic anabolic steroids has shown to cause atrial arrhythmias. Several studies have suggested that the interval from the peak to the end of the electrocardiographic T wave (Tp-e) may correspond to the transmural dispersion of repolarization and that increased Tp-e interval and Tp-e/QT ratio are associated with malignant ventricular arrhythmias. The aim of this study was to evaluate repolarization dispersion measured from the 12-lead surface electrocardiogram (including Tp-e interval, Tp-e/QT ratio, and Tp-e/cQT ratio) in bodybuilders who are using anabolic androgenic steroids (AAS).
METHODS: We selected a population of 33 competitive bodybuilders, including 15 actively using AAS for ≥ 2 years (users) and 18 who had never used AAS (nonusers), all men.
RESULTS: QT, cQT, QTd, cQTd, JT, and cJT were significantly increased in AAS users bodybulders compared to the nonusers (all P < 0.001). Tp-e interval, Tp-e/QT ratio, and Tp-e/cQT ratio were also significantly higher in AAS user group compared to the nonuser group (all P < 0.001). QRS duration was not different between the groups. There were negative correlation between E(m) and Tp-e, Tp-e/QT ratio, Tp-e/cQT ration (r = -0.657, P < 0.01; r = -0.607, P = 0.02; r = -0.583, P = 0.02; respectively).There were also negative correlation between S(m) and Tp-e, Tp-e/QT ratio, Tp-e/cQT ration (r = -0.681, P < 0.01; r = -0.549, P = 0.03; r = -0.544, P = 0.023; respectively).
CONCLUSION: In conclusion, we have presented a strong evidence suggesting that Tp-e interval, Tp-e/QT ratio, and Tp-e/QTc ratio were increased in AAS users, which suggest that there might be a link between AAS use and ventricular arrthymias and sudden death.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  Tp-e interval; Tp-e/QT Tp-e/QT ratio; Tp-e/QTc ratio; androgenic anabolic steroids; ventricular hypertrophy

Mesh:

Substances:

Year:  2015        PMID: 25631523      PMCID: PMC6931420          DOI: 10.1111/anec.12256

Source DB:  PubMed          Journal:  Ann Noninvasive Electrocardiol        ISSN: 1082-720X            Impact factor:   1.468


  48 in total

1.  One- and two-dimensional echocardiography in bodybuilders using anabolic steroids.

Authors:  A Urhausen; R Hölpes; W Kindermann
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1989

Review 2.  Pharmacoepidemiology of anabolic androgenic steroids: a review.

Authors:  Ingemar Thiblin; Anna Petersson
Journal:  Fundam Clin Pharmacol       Date:  2005-02       Impact factor: 2.748

3.  Are the cardiac effects of anabolic steroid abuse in strength athletes reversible?

Authors:  A Urhausen; T Albers; W Kindermann
Journal:  Heart       Date:  2004-05       Impact factor: 5.994

4.  QT dispersion in patients with different etiologies of left ventricular hypertrophy: the significance of QT dispersion in endurance athletes.

Authors:  Mehdi Zoghi; Cemil Gürgün; Oguz Yavuzgil; Azem Akilli; Cüneyt Türkoglu; Hakan Kültürsay; Mustafa Akin
Journal:  Int J Cardiol       Date:  2002-08       Impact factor: 4.164

5.  Patterns of QT dispersion in athletic and hypertensive left ventricular hypertrophy.

Authors:  Laura Maria Lonati; Gaia Magnaghi; Caterina Bizzi; Gastone Leonetti
Journal:  Ann Noninvasive Electrocardiol       Date:  2004-07       Impact factor: 1.468

6.  Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death.

Authors:  A W Haider; M G Larson; E J Benjamin; D Levy
Journal:  J Am Coll Cardiol       Date:  1998-11       Impact factor: 24.094

Review 7.  T(p-e)/QT ratio as an index of arrhythmogenesis.

Authors:  Prasad Gupta; Chinmay Patel; Harsh Patel; Srinivasa Narayanaswamy; Binu Malhotra; Jared T Green; Gan-Xin Yan
Journal:  J Electrocardiol       Date:  2008-09-14       Impact factor: 1.438

8.  Ventricular repolarization is prolonged in nondipper hypertensive patients: role of left ventricular hypertrophy and autonomic dysfunction.

Authors:  Claudio Passino; Armando Magagna; Fabrizio Conforti; Simona Buralli; Michaela Kozáková; Carlo Palombo; Michele Emdin
Journal:  J Hypertens       Date:  2003-02       Impact factor: 4.844

9.  Cardiac tissue Doppler in steroid users.

Authors:  A Krieg; J Scharhag; T Albers; W Kindermann; A Urhausen
Journal:  Int J Sports Med       Date:  2007-06-01       Impact factor: 3.118

10.  Left ventricular diastolic function in weight lifters.

Authors:  A C Pearson; M Schiff; D Mrosek; A J Labovitz; G A Williams
Journal:  Am J Cardiol       Date:  1986-12-01       Impact factor: 2.778

View more
  5 in total

Review 1.  Doping with anabolic androgenic steroids (AAS): Adverse effects on non-reproductive organs and functions.

Authors:  Eberhard Nieschlag; Elena Vorona
Journal:  Rev Endocr Metab Disord       Date:  2015-09       Impact factor: 6.514

Review 2.  Anabolic androgenic steroid abuse in the United Kingdom: An update.

Authors:  Carrie Mullen; Benjamin J Whalley; Fabrizio Schifano; Julien S Baker
Journal:  Br J Pharmacol       Date:  2020-03-03       Impact factor: 8.739

3.  Effect of ranolazine on Tp-e interval, Tp-e/QTc, and P-wave dispersion in patients with stable coronary artery disease.

Authors:  Murat Akcay; Metin Coksevim; Mustafa Yenercag
Journal:  J Arrhythm       Date:  2021-05-17

4.  Tpeak-Tend Interval during Pregnancy and Postpartum.

Authors:  Tomasz Kandzia; Grażyna Markiewicz-Łoskot; Przemysław Binkiewicz
Journal:  Int J Environ Res Public Health       Date:  2022-10-03       Impact factor: 4.614

5.  Evaluation of Electrocardiographic Ventricular Depolarization and Repolarization Variables in Type 1 Diabetes Mellitus.

Authors:  Mehmet Inanır; Yilmaz Gunes; Isa Sincer; Emrah Erdal
Journal:  Arq Bras Cardiol       Date:  2020-02       Impact factor: 2.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.